N E W S
4 October 2023
Employee Profile Marco Schaaf: Combining personal, professional and company growth.
6 September 2023
Milestone: Neuroplast reports patient inclusion completion in Phase II clinical trial for Traumatic Spinal
Cord Injury.
1 August 2023
Employee Profile Heleen Kessels: "Quality assurance should be more visible as a career opportunity."
24 June 2023
Employee Profile Michael Festjens: We have a profound impact on patients' lives.
5 June 2023
Employee Profile Chiemezie Nwakire: Stem cell therapies are going to change the world.
25 April 2023
Background: How Neuro-Cells® is made. From bloody bags of bone marrow to sophisticated syringes that regenerate futures of people with neurodegenerative diseases.
16 February 2023
Background: Living with spinal cord injury. "I live a rich life, but what if a stem cell technology could have saved my ability to walk?"
29 September 2022
Milestone: Neuroplast reports halfway patient inclusion in Phase II clinical trial for Traumatic Spinal
Cord Injury
8 September 2022
Neuroplast receives second orphan medicinal product designation for Neuro-Cells®, paving the way for application to both chronic and trauma-induced neurodegenerative diseases.
23 June 2022
What causes complications after stroke and how to prevent them? The department of neurosurgery of Maastricht University Medical Centre+ and clinical stage biotech Neuroplast start research on factors that cause delayed cerebral ischemia after subarachnoid hemorrhage.
21 June 2022
Why Stem Cell Technology for Neurodegenerative Diseases Requires a Paradigm Shift.
This article is taken from European Biopharmaceutical Review July 2022, pages 44-46. © Samedan Ltd
20 April 2022
New lab facility gives growing Neuroplast production independence and accelerates clinical pipeline expansion.
29 March 2022
Stem cell biotech Neuroplast enrolls first patient in Phase II clinical trial of transformative Neuro-Cells® treatment for Traumatic Spinal Cord Injury.
04 February 2022
Stem cell biotech Neuroplast has opened a second facility in Maastricht, the Netherlands.
17 November 2021
Dutch stem cell biotech Neuroplast secures € 10 million (US$ 11.5 million) in Series B funding to further advance its transformative stem cell therapy for Traumatic Spinal Cord Injury.
09 November 2021
Dutch stem cell biotech Neuroplast announces successful clinical Phase I trial with its Neuro-Cells® stem cell treatment for Traumatic Spinal Cord Injury.
21 October 2021
Dutch stem cell biotech Neuroplast appoints TiGenix founder Frank Luyten and Sanquin director Pieter
de Geus to its supervisory board.
19 November 2020
Neuro-Cells® in patient. Neuroplast BV announced the first patient with chronic spinal cord injury was treated with Neuro-Cells®.
18 February 2020
Neuroplast raises € 4 million for its stem cell-based technology to treat patients with Spinal Cord Injury.
01 May 2019
European Medicines Agency (EMA) has granted Orphan Drug Designation to Neuroplast treatment.